Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Overall survival (OS)

OS is defined as the time from randomization to death from any cause.

Time frame: Until death, assessed up to approximately 5 years

Investigator-assessed PFS

Investigator-assessed PFS is defined as the time from randomization to the first documented disease progression or death, whichever occurs first, based on investigator assessment per RECIST v1.1.

Time frame: Until progression or death, assessed up to approximately 4 years

Investigator-assessed confirmed ORR

Investigator-assessed confirmed ORR is defined as the percentage of participants with a confirmed CR or PR based on investigator assessment relative to the total number of participants.

Time frame: Until progression or death, assessed up to approximately 3 years

Duration of response (DOR)

DOR is defined as the time from first documented evidence of CR or PR until the first documented evidence of disease progression or death, whichever occurs first.

Time frame: Until progression or death, assessed up to approximately 4 years

Time to second Progression-free survival (PFS2)

PFS2 is defined as the time from randomization to second progression (ie, earliest of the subsequent progression events after initiation of a new anti-cancer treatment), or death from any cause, whichever occurs first.

Time frame: Assessed up to approximately 5 years

Incidence and severity of adverse events (AEs), as a measure of safety and tolerability of firmonertinib

An AE is defined as any unfavorable or unintended medical occurrence in a trial participant administered a pharmaceutical product, regardless of causal attribution.

Time frame: Assessed up to approximately 5 years

Change from baseline in safety-related clinical laboratory test results

Safety-related laboratory parameters include absolute neutrophil count, hemoglobin, platelet count, albumin, blood urea nitrogen (BUN), chloride, creatinine, potassium, sodium, alkaline phosphatase (ALP), alanine aminotransferase (ALT); aspartate aminotransferase (AST), total bilirubin. Each parameter is measured using its standard unit. Changes in participants' laboratory test values are evaluated by comparing baseline (pre-treatment) results with those obtained at prespecified time points during or following the treatment.

Time frame: Assessed up to approximately 5 years